{"id":95513,"date":"2025-11-10T14:47:42","date_gmt":"2025-11-10T19:47:42","guid":{"rendered":"https:\/\/ifintechworld.com\/?p=95513"},"modified":"2025-11-10T14:47:45","modified_gmt":"2025-11-10T19:47:45","slug":"regeneron-pharmaceuticals-inc-regn-discusses-factor-xi-development-program-and-clinical-data-in-hematology-pipeline-transcript","status":"publish","type":"post","link":"https:\/\/ifintechworld.com\/?p=95513","title":{"rendered":"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript"},"content":{"rendered":"
\n

Operator<\/strong><\/span><\/p>\n

Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for today’s call. [Operator Instructions] Please note that this conference call is being recorded. I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may begin.<\/p>\n<\/p><\/div>\n

\n

Ryan Crowe<\/strong><\/span>
Senior Vice President of Investor Relations & Strategic Analysis<\/i><\/span><\/p>\n

Thank you, Shannon. Good morning, and welcome to the inaugural Regeneron Roundtable Investor Event, the first in a series of presentations that will spotlight key opportunities across our pipeline.<\/p>\n

Today, we will focus on our Factor XI development program, which began initial Phase III studies earlier this year. Today’s roundtable features key R&D leaders from Regeneron, including Dr. George Yancopoulos, Board Co-Chair, President and Chief Scientific Officer; Dr. Andres Sirulnik, Senior Vice President and Clinical Development Unit Head, Hematology; and David — Dr. David Gutstein, Vice President and Global Program Head, Hematology.<\/p>\n

Before we begin, I would like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject<\/p>\n<\/p><\/div>\n

Read the full article here<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for today’s call. [Operator Instructions] Please note that this conference call is being recorded. I will now turn the call over to Ryan Crowe, Senior Vice President, Investor Relations. You may […]<\/p>\n","protected":false},"author":1,"featured_media":613,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"gallery","meta":{"footnotes":""},"categories":[236],"tags":[83],"class_list":["post-95513","post","type-post","status-publish","format-gallery","has-post-thumbnail","hentry","category-news","tag-featured","post_format-post-format-gallery"],"yoast_head":"\nRegeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript | iFintechWorld<\/title>\n<meta name=\"description\" content=\"Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ifintechworld.com\/?p=95513\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript | iFintechWorld\" \/>\n<meta property=\"og:description\" content=\"Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ifintechworld.com\/?p=95513\" \/>\n<meta property=\"og:site_name\" content=\"iFintechWorld\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-10T19:47:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-10T19:47:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"1200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"News Room\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"News Room\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ifintechworld.com\/?p=95513#article\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=95513\"},\"author\":{\"name\":\"News Room\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\"},\"headline\":\"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript\",\"datePublished\":\"2025-11-10T19:47:42+00:00\",\"dateModified\":\"2025-11-10T19:47:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=95513\"},\"wordCount\":209,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"keywords\":[\"Featured\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ifintechworld.com\/?p=95513#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ifintechworld.com\/?p=95513\",\"url\":\"https:\/\/ifintechworld.com\/?p=95513\",\"name\":\"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript | iFintechWorld\",\"isPartOf\":{\"@id\":\"https:\/\/ifintechworld.com\/#website\"},\"datePublished\":\"2025-11-10T19:47:42+00:00\",\"dateModified\":\"2025-11-10T19:47:45+00:00\",\"description\":\"Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for\",\"breadcrumb\":{\"@id\":\"https:\/\/ifintechworld.com\/?p=95513#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ifintechworld.com\/?p=95513\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ifintechworld.com\/?p=95513#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ifintechworld.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ifintechworld.com\/#website\",\"url\":\"https:\/\/ifintechworld.com\/\",\"name\":\"Repay Down\",\"description\":\"Latest Personal Finance News, Tips and Updates\",\"publisher\":{\"@id\":\"https:\/\/ifintechworld.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ifintechworld.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ifintechworld.com\/#organization\",\"name\":\"Repay Down\",\"url\":\"https:\/\/ifintechworld.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png\",\"width\":558,\"height\":90,\"caption\":\"Repay Down\"},\"image\":{\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61\",\"name\":\"News Room\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"contentUrl\":\"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png\",\"caption\":\"News Room\"},\"sameAs\":[\"https:\/\/ifintechworld.com\"],\"url\":\"https:\/\/ifintechworld.com\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript | iFintechWorld","description":"Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ifintechworld.com\/?p=95513","og_locale":"en_US","og_type":"article","og_title":"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript | iFintechWorld","og_description":"Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for","og_url":"https:\/\/ifintechworld.com\/?p=95513","og_site_name":"iFintechWorld","article_published_time":"2025-11-10T19:47:42+00:00","article_modified_time":"2025-11-10T19:47:45+00:00","og_image":[{"width":1200,"height":1200,"url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png","type":"image\/png"}],"author":"News Room","twitter_card":"summary_large_image","twitter_misc":{"Written by":"News Room","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ifintechworld.com\/?p=95513#article","isPartOf":{"@id":"https:\/\/ifintechworld.com\/?p=95513"},"author":{"name":"News Room","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61"},"headline":"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript","datePublished":"2025-11-10T19:47:42+00:00","dateModified":"2025-11-10T19:47:45+00:00","mainEntityOfPage":{"@id":"https:\/\/ifintechworld.com\/?p=95513"},"wordCount":209,"commentCount":0,"publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"keywords":["Featured"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ifintechworld.com\/?p=95513#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ifintechworld.com\/?p=95513","url":"https:\/\/ifintechworld.com\/?p=95513","name":"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript | iFintechWorld","isPartOf":{"@id":"https:\/\/ifintechworld.com\/#website"},"datePublished":"2025-11-10T19:47:42+00:00","dateModified":"2025-11-10T19:47:45+00:00","description":"Operator Welcome to the Regeneron conference call to discuss its Factor XI development program. My name is Shannon, and I will be your operator for","breadcrumb":{"@id":"https:\/\/ifintechworld.com\/?p=95513#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ifintechworld.com\/?p=95513"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ifintechworld.com\/?p=95513#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ifintechworld.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron Pharmaceuticals, Inc. (REGN) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline Transcript"}]},{"@type":"WebSite","@id":"https:\/\/ifintechworld.com\/#website","url":"https:\/\/ifintechworld.com\/","name":"Repay Down","description":"Latest Personal Finance News, Tips and Updates","publisher":{"@id":"https:\/\/ifintechworld.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ifintechworld.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ifintechworld.com\/#organization","name":"Repay Down","url":"https:\/\/ifintechworld.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/rep-logo-dark.png","width":558,"height":90,"caption":"Repay Down"},"image":{"@id":"https:\/\/ifintechworld.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/6224724fd4116361255b179dc5c70b61","name":"News Room","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ifintechworld.com\/#\/schema\/person\/image\/","url":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","contentUrl":"https:\/\/ifintechworld.com\/wp-content\/uploads\/2023\/04\/avatar_user_1_1682606986-96x96.png","caption":"News Room"},"sameAs":["https:\/\/ifintechworld.com"],"url":"https:\/\/ifintechworld.com\/?author=1"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/95513","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=95513"}],"version-history":[{"count":1,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/95513\/revisions"}],"predecessor-version":[{"id":95514,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/posts\/95513\/revisions\/95514"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=\/wp\/v2\/media\/613"}],"wp:attachment":[{"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=95513"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=95513"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ifintechworld.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=95513"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}